AR076627A1 - Composicion. uso.combinacion. kit. control temporal in vivo de enzimas activables degradadoras de matriz. recipiente - Google Patents
Composicion. uso.combinacion. kit. control temporal in vivo de enzimas activables degradadoras de matriz. recipienteInfo
- Publication number
- AR076627A1 AR076627A1 ARP090100823A ARP090100823A AR076627A1 AR 076627 A1 AR076627 A1 AR 076627A1 AR P090100823 A ARP090100823 A AR P090100823A AR P090100823 A ARP090100823 A AR P090100823A AR 076627 A1 AR076627 A1 AR 076627A1
- Authority
- AR
- Argentina
- Prior art keywords
- cathepsin
- amde
- composition
- mmp
- activator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22015—Cathepsin L (3.4.22.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Marine Sciences & Fisheries (AREA)
Abstract
Reivindicacion 1: El uso de una enzima degradadora de la matriz activable (AMDE) para la formulacion de un medicamento para administracion subepidérmica en una cantidad suficiente para degradar uno o más componentes de la ECM, en donde la AMDE está formulada en forma inactiva. Reivindicacion 2: Una composicion farmacologica formulada para administracion subepidérmica para su uso en el tratamiento de una enfermedad o condicion de la ECM, que comprende una enzima degradadora de la matriz activable (AMDE) en una cantidad suficiente para degradar uno o más componentes de la ECM, en donde la AMDE está formulada en forma inactiva. Reivindicacion 4: Una composicion farmacologica formulada para administracion subepidérmica para su uso en el tratamiento de una enfermedad o condicion de la ECM, que comprende una enzima degradadora de la matriz activable (AMDE) y un activador en una cantidad suficiente para degradar uno o más componentes de la ECM, en donde la AMDE está inactiva en la ECM en la ausencia del activador; y el activador provee una condicion de activacion para la enzima, de modo que la AMDE esté activa. Reivindicacion 8: El uso o la composicion de cualquiera de las reivindicaciones 3-7, en donde el activador está formulado en la misma composicion que la AMDE o en una composicion separada. Reivindicacion 9: El uso o la composicion de cualquiera de las reivindicaciones 3-8, en donde las condiciones de activacion son seleccionadas entre pH, fuerza ionica, temperatura y iones metálicos. Reivindicacion 15: El uso o la composicion de cualquiera de las reivindicaciones 1-14, en donde la AMDE se selecciona entre una catepsina, una calpaína y una heparanasa. Reivindicacion 16: El uso o la composicion de la reivindicacion 15, en donde la AMDE es una catepsina y la catepsina es una cisteína proteasa o aspártico proteasa. Reivindicacion 17: El uso o la composicion de la reivindicacion 16, en donde a catepsina se selecciona entre catepsina S, catepsina K, catepsina L, catepsina B, catepsina C, catepsina H, catepsina F, catepsina O, catepsina R, catepsina y, catepsina W, catepsina D y catepsina E. Reivindicacion 19: El uso o la composicion de la reivindicacion 16 o reivindicacion 17, en donde la catepsina tiene una secuencia de aminoácidos seleccionada entre cualquiera de las SEC ID N°: 57, 60, 1, 65, 180, 68, 71, 74, 77, 183, 186, 189, 80, 195, 90, 93 y 96, o es una variante alélica o de especies u otra variante de cualquiera de las SEC ID N°: 57, 60, 1, 65, 180, 68, 71, 74, 77, 183, 186, 189, 80, 195, 90, 93 y 96. Reivindicacion 27: El uso o la composicion de cualquiera de las reivindicaciones 14-26, en donde el activador provee la condicion de activacion de pH ácido como una solucion amortiguadora del pH. Reivindicacion 28: El uso o la composicion de la reivindicacion 27, en donde la solucion amortiguadora contiene un ácido seleccionado entre ácido 2-(N-morfolino)etansulfonico (MES), ácido acético, ácido cítrico, fosfato cítrico e histidina. Reivindicacion 31: El uso o la composicion de cualquiera de las reivindicaciones 20-30, en donde la AMDE es una enzima lisosomica. Reivindicacion 37: El uso o la composicion de cualquiera de las reivindicaciones 1-36, en donde la AMDE es un zimogeno. Reivindicacion 38: El uso o la composicion de cualquiera de las reivindicaciones 1-36, en donde la AMDE es una proteína madura que está en una forma de cadena simple o de dos cadenas. Reivindicacion 40: Una composicion farmacologica para su uso en el tratamiento de una enfermedad o condicion de la ECM, que comprende una enzima degradadora de la matriz activable (AMDE) y un activador en una cantidad suficiente para degradar uno o más componentes de la ECM, en donde la AMDE está inactiva en la ausencia del activador; el activador provee una condicion de activacion para la enzima, de modo que la AMDE está activa; y el activador se selecciona entre iones metálicos, temperatura y fuerza ionica. Reivindicacion 43: El uso o la composicion farmacologica de cualquiera de las reivindicaciones 39-42, en donde la AMDE se selecciona entre una elastasa pancreática, una elastasa-2A, una elastasa-2B, una elastasa de neutrofilo, una proteinasa-3, una elastasa vascular endogena, una catepsina G, una quimasa de mastocitos, una triptasa de mastocitos, una plasmina, una trombina, una granzima B, una catepsina S, una catepsina K, una catepsina L, una catepsina B, una catepsina C, una catepsina H, una catepsina F, una catepsina O, una catepsina R, una catepsina V, una catepsina W, una calpaína 1, una calpaína 2, una legumaína, una catepsina Z, una catepsina D, una catepsina E, una MMP-1, una MMP-8, una MMP-13, una MMP-18, una MMP-2, una MMP-9, una MMP-3, una MMP-10, una MMP-11, una MMP-7, una MMP-26, una MMP-12, una MMP-14, una MMP-15, una MMP-16, una MMP-17, una MMP-19, una MMP-20, una ADAMTS-1, una ADAMTS-2, una ADAMTS-3, una ADAMTS-4, una ADAMTS-5, una ADAMTS-14 y una heparanasa o variantes alélicas o de especies u otras variantes de las mismas. Reivindicacion 47: El uso o la composicion farmacologica de cualquiera de las reivindicaciones 1-46, en donde dicho uno o más componentes de la ECM se selecciona entre un colágeno, una elastina, una fibronectina o un proteoglicano. Reivindicacion 50: El uso o la composicion farmacologica de cualquiera de las reivindicaciones 1-49, en donde la enfermedad o condicion de la ECM es una enfermedad o condicion mediada por colágeno. Reivindicacion 51: El uso o la composicion farmacologica de la reivindicacion 50, en donde la una enfermedad o condicion mediada por colágeno se selecciona entre celulitis, enfermedad de Dupuytren, enfermedad de Peyronie, fibrosis de Ledderhose, articulaciones rígidas, cicatrices existentes, esclerodermia, linfedema y colitis colagenosa. Reivindicacion 53: El uso o la composicion farmacologica de la reivindicacion 51, en donde la enfermedad o condicion mediada por colágeno comprende cicatrices existentes que son seleccionadas entre adhesiones quirurgicas, queloides, cicatrices hipertroficas y cicatrices deprimidas. Reivindicacion 55: Una composicion farmacologica para su uso en el tratamiento de una enfermedad o condicion mediada por colágeno, que comprende una catepsina L activable y un activador en una cantidad suficiente para degradar uno o más componentes de colágeno de la ECM, en donde la catepsina L activable está inactiva en la ausencia del activador; el activador provee una condicion de activacion para la enzima, de modo que la catepsina L activable está activa; y la condicion de activacion es pH ácido. Reivindicacion 57: Una combinacion, que comprende una enzima degradadora de la matriz activable; un activador; y uno o más agentes seleccionados entre otros agentes biologicos, compuestos de moléculas pequenas, agentes dispersantes, anestésicos y vasoconstrictores, en donde la AMDE está inactiva en la ausencia del activador; y el activador provee una condicion de activacion para la enzima, de modo que la AMDE está activa. Reivindicacion 58: La combinacion de la reivindicacion 57, en donde el activador provee una condicion de activacion seleccionada entre pH, iones metálicos, temperatura y fuerza ionica. Reivindicacion 61: La combinacion de cualquiera de las reivindicaciones 57-60, en donde el otro agente es un agente dispersante que es una hialuronidasa. Reivindicacion 63: La combinacion de la reivindicacion 61 o reivindicacion 62, en donde la hialuronidasa es una PH20, o una forma truncada de la misma. Reivindicacion 66: La combinacion de la reivindicacion 65 en donde la hialuronidasa tiene una secuencia de aminoácidos indicada en la SEC ID N°:226-231, o es una variante alélica o de especie u otra variante de las mismas. Reivindicacion 69: La combinacion de cualquiera de las reivindicaciones 57-68, en donde el otro agente es un anestésico que es una lidocaína. Reivindicacion 71: La combinacion de cualquiera de las reivindicaciones 57-70, en donde el otro agente es un vasoconstrictor que es un agonista de receptor adrenérgico alfa. Reivindicacion 72: La combinacion de la reivindicacion 71, en donde el agonista de receptor adrenérgico alfa se selecciona entre levonordefrina, epinefrina y norepinefrina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6866708P | 2008-03-06 | 2008-03-06 | |
US12772508P | 2008-05-14 | 2008-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076627A1 true AR076627A1 (es) | 2011-06-29 |
Family
ID=41017153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100823A AR076627A1 (es) | 2008-03-06 | 2009-03-06 | Composicion. uso.combinacion. kit. control temporal in vivo de enzimas activables degradadoras de matriz. recipiente |
Country Status (16)
Country | Link |
---|---|
US (2) | US9833498B2 (es) |
EP (1) | EP2274004B1 (es) |
JP (2) | JP5709531B2 (es) |
KR (3) | KR20130106893A (es) |
AR (1) | AR076627A1 (es) |
AU (1) | AU2009220094B2 (es) |
BR (1) | BRPI0909622A2 (es) |
CA (1) | CA2718549C (es) |
CL (2) | CL2009000541A1 (es) |
CO (1) | CO6331294A2 (es) |
ES (1) | ES2586765T3 (es) |
HK (1) | HK1150554A1 (es) |
IL (1) | IL207293A (es) |
MX (1) | MX2010009806A (es) |
TW (1) | TWI395593B (es) |
WO (1) | WO2009111083A2 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2298874A1 (en) | 2002-12-16 | 2011-03-23 | Halozyme, Inc. | Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof |
US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
TWI532498B (zh) | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
WO2009128917A2 (en) * | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
JP5670913B2 (ja) | 2008-12-09 | 2015-02-18 | ハロザイム インコーポレイテッド | 延長された可溶性ph20ポリペプチドおよびその使用 |
WO2010102262A1 (en) * | 2009-03-06 | 2010-09-10 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
MX348420B (es) | 2010-07-20 | 2017-06-12 | Halozyme Inc | Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios. |
CA2810668A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
WO2012048291A2 (en) | 2010-10-08 | 2012-04-12 | Proteapex Therapeutics Llc | Compositions and methods for inhibition of mmp:mmp-substrate interactions |
US8740982B2 (en) | 2010-10-26 | 2014-06-03 | Kyphon Sarl | Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis |
US8404268B2 (en) | 2010-10-26 | 2013-03-26 | Kyphon Sarl | Locally targeted anti-fibrotic agents and methods of use |
US9414930B2 (en) | 2010-10-26 | 2016-08-16 | Kyphon SÀRL | Activatable devices containing a chemonucleolysis agent |
WO2012155212A1 (en) * | 2011-05-18 | 2012-11-22 | David Chin | Method of treating excessive collagen formation |
JP5860651B2 (ja) * | 2011-09-30 | 2016-02-16 | オリンパス株式会社 | ホタル由来ルシフェラーゼ |
FR2984128A1 (fr) * | 2011-12-14 | 2013-06-21 | Oreal | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux sensibles. |
FR2984129B1 (fr) * | 2011-12-14 | 2014-01-10 | Oreal | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu |
FR2984130A1 (fr) * | 2011-12-14 | 2013-06-21 | Oreal | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux vieillies ou senescentes. |
FR2984127A1 (fr) * | 2011-12-14 | 2013-06-21 | Oreal | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux grasses et/ou a tendance grasse. |
SI2833905T1 (en) | 2012-04-04 | 2018-08-31 | Halozyme, Inc. | Combination therapy with hyaluronidase and tumane-directed taxane |
WO2013165304A1 (en) | 2012-04-30 | 2013-11-07 | Yo Proteins Ab | Methods for modification of tissues |
WO2014107745A1 (en) | 2013-01-07 | 2014-07-10 | Halozyme, Inc. | Metal sensitive mutants of matrix metalloproteases and uses thereof |
WO2014172526A1 (en) * | 2013-04-18 | 2014-10-23 | Drexel University | Novel methods of use of biomimetic proteoglycans |
US9393177B2 (en) | 2013-08-20 | 2016-07-19 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
AU2014329412B2 (en) * | 2013-10-03 | 2020-02-27 | Harrow Ip, Llc | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
FI127924B (en) * | 2014-02-27 | 2019-05-31 | Oy Medix Biochemica Ab | METHOD OF MEASURING MMP-8 ACTIVATION |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
PL3388075T3 (pl) | 2015-03-27 | 2023-12-11 | Immatics Biotechnologies Gmbh | Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem różnych nowotworów |
US10493247B2 (en) | 2016-03-15 | 2019-12-03 | Medtronic Holding Company Sàrl | Devices for delivering a chemical denervation agent and methods of use |
WO2018039420A1 (en) | 2016-08-25 | 2018-03-01 | Imprimis Pharmaceuticals, Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
US11766467B2 (en) | 2017-09-01 | 2023-09-26 | University Of Wyoming | Methods of treating wounds using cathepsin K inhibitors |
US10758559B1 (en) | 2017-09-01 | 2020-09-01 | University Of Wyoming | Targeting cathepsin K to facilitate wound healing |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
EP3793689A1 (en) * | 2018-05-15 | 2021-03-24 | Translate Bio, Inc. | Subcutaneous delivery of messenger rna |
CA3130763A1 (en) | 2019-02-25 | 2020-09-03 | Ginkgo Bioworks, Inc. | Biosynthesis of cannabinoids and cannabinoid precursors |
JP7316647B2 (ja) * | 2019-07-16 | 2023-07-28 | 日本メナード化粧品株式会社 | カテプシンv活性促進剤及びgata-3産生抑制剤 |
CN114929261A (zh) | 2020-02-17 | 2022-08-19 | 生物测试股份公司 | 凝血因子viii的皮下施用 |
US11370973B2 (en) | 2020-07-10 | 2022-06-28 | Saudi Arabian Oil Company | Processes and systems for producing one or more of benzene, toluene, or mixed xylenes |
KR102486046B1 (ko) * | 2020-12-14 | 2023-01-11 | 주식회사 뉴온바이오 | 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물 |
TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539794A (en) | 1967-09-12 | 1970-11-10 | American Cyanamid Co | Self-contained chemiluminescent lighting device |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US3847770A (en) | 1972-04-10 | 1974-11-12 | Continental Can Co | Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
LU76148A1 (es) | 1976-11-08 | 1978-07-10 | ||
SU787035A1 (ru) | 1978-01-11 | 1980-12-15 | Всесоюзный научно-исследовательский и испытательный институт медицинской техники | Устройство дл введени лекарственных препаратов |
US4202314A (en) | 1978-11-20 | 1980-05-13 | Busygin Valery P | Device for injection of medicinal preparations |
JPS57128634A (en) * | 1981-02-03 | 1982-08-10 | Eisai Co Ltd | Elastase-containing compound increasing absorption |
ATE32432T1 (de) | 1981-08-10 | 1988-02-15 | Duphar Int Res | Automatische injektionsspritze. |
US4645668A (en) * | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
US4687610A (en) | 1986-04-30 | 1987-08-18 | E. I. Du Pont De Neumours And Company | Low crystallinity polyester yarn produced at ultra high spinning speeds |
SE457417B (sv) | 1987-04-14 | 1988-12-27 | Astra Meditec Ab | Automatisk tvaakammarspruta, foerfarande foer blandning och injicering med sprutan samt ampull foer tvaakammarspruta |
GB2205643B (en) | 1987-05-08 | 1991-03-13 | Farmos Group Limited | Type iii collagen degradation assay |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
DE3921528A1 (de) | 1989-06-30 | 1991-01-10 | Draegerwerk Ag | Messzelle fuer den elektrochemischen gasnachweis |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5051449A (en) | 1991-02-27 | 1991-09-24 | Kligman Albert M | Treatment of cellulite with retinoids |
GB9105893D0 (en) | 1991-03-20 | 1991-05-08 | Orion Yhtymae Oy | Bone resorption assay based on a peptide liberated during collagen degradation |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5171081A (en) | 1992-05-29 | 1992-12-15 | Pita Joe W | Chemiluminescent reactive vessel |
CA2098777A1 (en) | 1992-06-19 | 1993-12-20 | Yukio Fujisawa | Production of human cathepsin and its use |
JPH0775573A (ja) | 1992-06-19 | 1995-03-20 | Takeda Chem Ind Ltd | ヒトカテプシンの製造法および該酵素含有製剤 |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
JPH06192124A (ja) | 1992-12-25 | 1994-07-12 | Toray Ind Inc | 血液細胞増加剤 |
US5353961A (en) | 1993-01-15 | 1994-10-11 | Reseal International Limited Partnership | Dual chamber dispenser |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
GB9319103D0 (en) | 1993-09-15 | 1993-11-03 | Unilever Plc | Skin care method & composition |
US5395326A (en) | 1993-10-20 | 1995-03-07 | Habley Medical Technology Corporation | Pharmaceutical storage and mixing syringe having high pressure assisted discharge |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
ES2168361T3 (es) * | 1994-03-17 | 2002-06-16 | Max Delbrueck Centrum | Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo. |
DE69503849T2 (de) | 1994-03-31 | 1999-04-01 | Amgen Inc., Thousand Oaks, Calif. | Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten |
US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
US5496284A (en) | 1994-09-27 | 1996-03-05 | Waldenburg; Ottfried | Dual-chamber syringe & method |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6544767B1 (en) * | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
DE4445969C1 (de) | 1994-12-22 | 1996-03-14 | Schott Glaswerke | Spritzenzylinder für eine Zweikammer-Fertigspritze, Zweikammer-Fertigspritze und Verfahren zum Herstellen und Füllen derselben |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5536499A (en) | 1995-02-24 | 1996-07-16 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions for reducing or preventing signs of cellulite |
US5523090A (en) | 1995-02-24 | 1996-06-04 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin treatment composition |
US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
US6470216B1 (en) | 1995-05-05 | 2002-10-22 | Thermage, Inc. | Method for smoothing contour irregularities of skin surface |
US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5705170A (en) | 1995-10-24 | 1998-01-06 | Plantech International, Inc. | Herbal cellulite treatments |
US5747322A (en) | 1996-05-09 | 1998-05-05 | The Regents Of The University Of California | Recombinant crab collagenase |
US5976556A (en) | 1996-06-13 | 1999-11-02 | Active Organics, Inc. | Combination of acid protease enzymes and acidic buffers and uses thereof |
US5667793A (en) | 1996-08-02 | 1997-09-16 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions for treating cellulite |
US5776759A (en) | 1996-09-26 | 1998-07-07 | Incyte Pharmaceuticals, Inc. | Two novel human cathepsin proteins |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6193963B1 (en) | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US5830741A (en) * | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
US6071526A (en) | 1997-03-27 | 2000-06-06 | S.W. Patentverwertungs Ges M.B. H. | Cosmetic or cosmetic product for firming and soothing the skin in particular in the case of cellulite |
US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
EP0998572A2 (en) * | 1997-07-25 | 2000-05-10 | Du Pont Pharmaceuticals Company | Aggrecan degrading metallo proteases |
FR2767833B1 (fr) | 1997-08-29 | 2001-03-02 | Oreal | Polypeptide isole de l'epiderme et son utilisation |
US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US6153207A (en) | 1998-03-05 | 2000-11-28 | Pugliese; Peter T. | Anti-cellulite pantyhose |
WO1999045964A1 (en) | 1998-03-12 | 1999-09-16 | Shearwater Polymers, Incorporated | Poly(ethylene glycol) derivatives with proximal reactive groups |
KR20010041902A (ko) | 1998-03-16 | 2001-05-25 | 데이비드 엠 모이어 | 포유류의 피부 내의 셀룰라이트를 감소시키는 방법 |
US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
CN1314992A (zh) | 1998-07-03 | 2001-09-26 | 奈勒斯菲尔德控制有限公司 | 流体测量的方法和装置 |
US6031005A (en) | 1998-08-03 | 2000-02-29 | Easterling; W. Jerry | Composition and method for treating Peyronie's disease and related connective tissue disorders |
US6443914B1 (en) | 1998-08-10 | 2002-09-03 | Lysonix, Inc. | Apparatus and method for preventing and treating cellulite |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6060474A (en) | 1998-11-05 | 2000-05-09 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method for preventing scar tissue formation |
CA2383486A1 (en) | 1999-02-01 | 2000-08-03 | Darren Lezdey | Treatment of bladder and gastrointestinal mastocytosis |
DK1173198T3 (da) * | 1999-04-29 | 2004-04-13 | Ista Pharmaceuticals Inc | Anvendelse af en bestemt hyaluronidase til eliminering af ar på, uigennemsigtighed og uklarhed på hornhinden |
US6022539A (en) | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
US6656701B2 (en) | 1999-07-16 | 2003-12-02 | Actim Organics, Inc | Combination of acid protease enzymes and acidic buffers and uses thereof |
US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
AU6918700A (en) | 1999-08-20 | 2001-03-19 | Howard Murad | Pharmaceutical compositions and methods for reducing the appearance of cellulite |
ITMI991894A1 (it) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
US6355243B1 (en) | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
EP1259562B1 (en) | 1999-12-22 | 2006-02-15 | Nektar Therapeutics Al, Corporation | Sterically hindered derivatives of water soluble polymers |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
US20030040701A1 (en) | 1999-12-28 | 2003-02-27 | Dalmose Asger Lau | Dual chamber syringe with a dual function piston |
US20030212021A1 (en) * | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
GB2375965B (en) | 2000-01-28 | 2004-09-01 | Novo Nordisk As | A dose setting limiter |
US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
AU2001241770A1 (en) * | 2000-02-28 | 2001-09-12 | Millennium Pharmaceuticals, Inc. | 18036, a novel calpain-like protease and uses thereof |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
EP1762236B1 (en) | 2000-05-12 | 2015-07-15 | Septodont Holding SAS | Formulations of alpha adrenergic receptor antagonists and their uses |
AU7485301A (en) | 2000-05-16 | 2001-11-26 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
US20020106388A1 (en) | 2000-11-24 | 2002-08-08 | Pugliese Peter T. | Formulation of flavones and isoflavones for treatment of cellulite |
ATE505204T1 (de) | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
CA2443018A1 (en) * | 2001-04-06 | 2002-10-17 | Cristiano Alberto Ribeiro Santana | Papaine containing pharmaceutical formulation resp. its use |
CA2349506C (en) * | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
EP1446438A2 (en) | 2001-11-07 | 2004-08-18 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
US6972005B2 (en) | 2002-05-10 | 2005-12-06 | Boehm Jr Frank H | Dual chamber syringe and dual lumen needle |
US6682904B1 (en) | 2002-08-15 | 2004-01-27 | Deliatroph Pharmaceuticals, Inc. | Specific inhibitors of hyaluronidase 2, and methods of identifying and using same |
KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
EP2298874A1 (en) * | 2002-12-16 | 2011-03-23 | Halozyme, Inc. | Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof |
MXPA05009169A (es) | 2003-02-26 | 2005-11-17 | Nektar Therapeutics Al Corp | Conjugados de polimero-porcion del factor viii. |
NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
ES2725808T3 (es) | 2003-05-23 | 2019-09-27 | Nektar Therapeutics | Derivados de PEG que contienen dos cadenas de PEG |
US20050042213A1 (en) | 2003-08-14 | 2005-02-24 | Insight Biopharmaceuticals Ltd. | Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
US7572613B2 (en) * | 2004-06-25 | 2009-08-11 | Klein Jeffrey A | Drug delivery system for accelerated subcutaneous absorption |
US7854929B2 (en) * | 2005-01-21 | 2010-12-21 | The Research Foundation Of State University Of New York | Method for treating lateral epicondylitis using collagenase |
US20070224184A1 (en) | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
WO2006091870A2 (en) | 2005-02-25 | 2006-08-31 | Temple University- Of The Commonwealth System Of Higher Education | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis |
EP1907032A2 (en) | 2005-06-30 | 2008-04-09 | Mallinckrodt, Inc. | Dual chamber syringe |
US20070003541A1 (en) * | 2005-07-01 | 2007-01-04 | Rodolfo Faudoa | Methods and compositions for therapeutics |
US20070004036A1 (en) * | 2005-07-01 | 2007-01-04 | Rodolfo Faudoa | Methods and compositions for keratinocyte culture |
US20070128685A1 (en) * | 2005-07-01 | 2007-06-07 | Rodolfo Faudoa | Methods and compositions for cell culture |
US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
US20080131500A1 (en) * | 2006-12-04 | 2008-06-05 | The Board Of Regents Of The University Of Texas System | Methods and compositions for rapid inactivation of proteins |
KR20140130512A (ko) | 2008-03-06 | 2014-11-10 | 할로자임, 아이엔씨 | 가용성 히알루로니다아제의 대규모 제조 |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
WO2009128917A2 (en) * | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
JP5670913B2 (ja) | 2008-12-09 | 2015-02-18 | ハロザイム インコーポレイテッド | 延長された可溶性ph20ポリペプチドおよびその使用 |
WO2010102262A1 (en) | 2009-03-06 | 2010-09-10 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
HUE036081T2 (hu) | 2009-03-09 | 2018-06-28 | Bioatla Llc | Mirac proteinek |
CA2810668A1 (en) * | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
KR101721678B1 (ko) | 2012-03-08 | 2017-03-31 | 할로자임, 아이엔씨 | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 |
-
2009
- 2009-03-05 TW TW098107084A patent/TWI395593B/zh not_active IP Right Cessation
- 2009-03-06 BR BRPI0909622A patent/BRPI0909622A2/pt not_active IP Right Cessation
- 2009-03-06 KR KR1020137024682A patent/KR20130106893A/ko not_active Application Discontinuation
- 2009-03-06 MX MX2010009806A patent/MX2010009806A/es active IP Right Grant
- 2009-03-06 CA CA2718549A patent/CA2718549C/en not_active Expired - Fee Related
- 2009-03-06 CL CL2009000541A patent/CL2009000541A1/es unknown
- 2009-03-06 US US12/381,063 patent/US9833498B2/en active Active
- 2009-03-06 AR ARP090100823A patent/AR076627A1/es unknown
- 2009-03-06 WO PCT/US2009/001486 patent/WO2009111083A2/en active Application Filing
- 2009-03-06 EP EP09716286.1A patent/EP2274004B1/en active Active
- 2009-03-06 AU AU2009220094A patent/AU2009220094B2/en not_active Ceased
- 2009-03-06 JP JP2010549679A patent/JP5709531B2/ja not_active Expired - Fee Related
- 2009-03-06 KR KR1020157004822A patent/KR101647933B1/ko active IP Right Grant
- 2009-03-06 ES ES09716286.1T patent/ES2586765T3/es active Active
- 2009-03-06 KR KR1020107022203A patent/KR20100135779A/ko not_active IP Right Cessation
-
2010
- 2010-07-29 IL IL207293A patent/IL207293A/en not_active IP Right Cessation
- 2010-09-08 CO CO10111097A patent/CO6331294A2/es not_active Application Discontinuation
-
2011
- 2011-05-12 HK HK11104693.9A patent/HK1150554A1/zh not_active IP Right Cessation
-
2013
- 2013-07-18 CL CL2013002070A patent/CL2013002070A1/es unknown
- 2013-10-02 JP JP2013207338A patent/JP2014043449A/ja active Pending
-
2014
- 2014-04-02 US US14/243,805 patent/US9775889B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2586765T3 (es) | 2016-10-18 |
WO2009111083A2 (en) | 2009-09-11 |
BRPI0909622A2 (pt) | 2019-09-24 |
EP2274004A2 (en) | 2011-01-19 |
CL2013002070A1 (es) | 2013-11-15 |
US9775889B2 (en) | 2017-10-03 |
MX2010009806A (es) | 2010-11-30 |
US20100003237A1 (en) | 2010-01-07 |
US20140271609A1 (en) | 2014-09-18 |
HK1150554A1 (zh) | 2012-01-06 |
US9833498B2 (en) | 2017-12-05 |
CA2718549C (en) | 2016-08-09 |
TW200944227A (en) | 2009-11-01 |
KR20160073346A (ko) | 2016-06-24 |
EP2274004B1 (en) | 2016-06-01 |
WO2009111083A3 (en) | 2010-03-25 |
KR20100135779A (ko) | 2010-12-27 |
CL2009000541A1 (es) | 2009-10-09 |
JP2011517318A (ja) | 2011-06-02 |
KR20130106893A (ko) | 2013-09-30 |
JP2014043449A (ja) | 2014-03-13 |
IL207293A (en) | 2016-12-29 |
AU2009220094A1 (en) | 2009-09-11 |
IL207293A0 (en) | 2010-12-30 |
AU2009220094B2 (en) | 2013-11-07 |
CA2718549A1 (en) | 2009-09-11 |
JP5709531B2 (ja) | 2015-04-30 |
CO6331294A2 (es) | 2011-10-20 |
KR101647933B1 (ko) | 2016-08-11 |
TWI395593B (zh) | 2013-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076627A1 (es) | Composicion. uso.combinacion. kit. control temporal in vivo de enzimas activables degradadoras de matriz. recipiente | |
JP2011517318A5 (es) | ||
Itoh et al. | Matrix metalloproteinases in cancer | |
Rao et al. | Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor | |
Smith et al. | Ovarian tissue remodeling: role of matrix metalloproteinases and their inhibitors | |
Ra et al. | Control of matrix metalloproteinase catalytic activity | |
ES2296788T3 (es) | Desbridador de heridas enzimatico estable. | |
JP5649589B2 (ja) | マトリックスメタロプロテアーゼ1の温度感受性突然変異体およびその使用 | |
KR920703803A (ko) | 활성화 피브린 용해성과 항-혈전성 단백질 | |
EP2852403B1 (en) | Methods for modification of tissues | |
Takahashi et al. | Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition | |
CA2194692A1 (en) | Fibrin(ogen) degradation and clot lysis by fibrinolytic matrix metalloproteinase | |
Shankar et al. | Protease enzymes: highlights on potential of proteases as therapeutics agents | |
US6787135B2 (en) | Modification of vitreal matrix metalloproteinase activity | |
US20150297687A1 (en) | Protease compositions for the treatment of damaged tissue | |
AU2013202011C1 (en) | In vivo temporal control of activatable matrix-degrading enzymes | |
US20100008898A1 (en) | Chymotrypsin from lucilia sericata larvae and its use for the treatment of wounds | |
US20150196625A9 (en) | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof | |
VJ et al. | Matrix metalloproteinases and hypertension: a link between left ventricular hypertrophy and diastolic dysfunction? | |
Kucharz et al. | Degradation | |
Watanabe et al. | Activation of progelatinase B in synovial fluids of patients with rheumatoid arthritis, with reference to stromelysin-1 and tissue inhibitor of matrix metalloproteinase-1 | |
Bennett et al. | Matrix metalloproteinases (matrixins) and their inhibitors (TIMPs) in angiogenesis | |
Parks | Role of metalloproteinases in epithelial repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |